Document is current
Any future updates will be listed below
-
Authors
Namba, Kenichi https://orcid.org/0000-0002-5016-851X
Takase, Hiroshi
Usui, Yoshihiko
Nitta, Fumihiko
Maruyama, Kazuichi
Kusuhara, Sentaro
Takeuchi, Masaki
Azumi, Atsushi
Yanai, Ryoji
Kaneko, Yutaka
Hasegawa, Eiichi
Nakai, Kei
Tsuruga, Hidekazu
Morita, Kazuo
Kaburaki, Toshikatsu
-
Clinical Trials BETA
Clinical trials referenced in this document:
umin000032390 at UMIN JapanDocuments that mention this clinical trial
Multicenter, retrospective, observational study for the Treatment Pattern of systemic corticoSTERoids for relapse of non-infectious uveitis accompanying Vogt-Koyanagi-Harada disease or sarcoidosis
https://doi.org/10.1007/s10384-021-00897-7
-
Funding
Funding for this research was provided by:
AbbVie GK
- License Information
-
More Information
Article History
Received: 30 May 2021
Accepted: 24 November 2021
First Online: 19 January 2022
Declarations
:
: K. Namba, Grant (AbbVie, Mitsubishi Tanabe, Eisai, EP-CRSU), Speaker fee (Alcon, Pfizer, Novartis, Kowa, Senju, Mitsubishi Tanabe, Eisai, AbbVie, Santen, Celgene); H. Takase, Personal fee (Santen, Novartis, AbbVie, Senju, Eisai, Otsuka) and has a patent pending (Japanese Patent Application No. 2019–107483); Y. Usui, Grant (ROHTO), Personal fee (Santen, Senju, Alcon, Kowa, AbbVie, Eisai, Mitsubishi Tanabe, Wakamoto, Novartis); F. Nitta, None; K. Maruyama, Grant (TOPCON); S. Kusuhara, Grant (Bayer, Alcon), Personal fee (Alcon, Bayer, Eisai, AbbVie, Kowa, Santen, Senju, Sanofi, Mitsubishi Tanabe, HOYA, Charmant); M. Takeuchi, None; A. Azumi, None; R. Yanai, None; Y. Kaneko, Grant (AbbVie); E. Hasegawa, Grant (AbbVie); K. Nakai, None; H. Tsuruga, Employee of AbbVie and owns AbbVie stocks; K. Morita, Employee of AbbVie; T. Kaburaki, Grant (Santen, Eisai, Novartis, AbbVie, Kowa, Senju, Wakamoto), Personal fee (AbbVie, Santen, Novartis, Eisai, Mitsubishi Tanabe, Kowa, Wakamoto, Senju, Ono).
